OXIS INTERNATIONAL INC Form SC 13G February 14, 2007

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED

PURSUANT TO RULE 13d-2(b)

Under the Securities Exchange Act of 1934 (Amendment No.)*

OXIS International, Inc.

(Name of Issuer)

Common Shares, par value \$0.001

(Title of Class of Securities)

691829402

(CUSIP Number)

December 31, 2006

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- o Rule 13d-1(b)
- x Rule 13d-1(c)
- o Rule 13d-1(d)

^{*}The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 691829402

1.	Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only) TorreyPines Therapeutics, Inc.			
2.	Check the Appropriate Box if a Member of a Group (See Instructions)			
	(a)	0	•	
	(b)	0		
3.	SEC Use Only			
4.	Citizenship or Place of Organization Delaware			
Number of	5.		Sole Voting Power 13,982,567	
Shares Beneficially Owned by	6.		Shared Voting Power 0	
Each Reporting Person With	7.		Sole Dispositive Power 13,982,567	
	8.		Shared Dispositive Power 0	
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 13,982,567			
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o			
11.	Percent of Class Represented by Amount in Row (9) 31.4%			
12.	Type of Reporting Person (See Instructions) CO			

2

Item 1.				
110111 11	(a)	Name of Issuer		
		Oxis International, Inc.		
	(b)	Address of Issuer s Principal Executive Offices		
		323 Vintage Park Drive, Suite	е В	
		Foster City, CA 94404		
		, , , , , , , , , , , , , , , , , , ,		
Item 2.				
	(a)	Name of Person Filing		
	(b)	TorreyPines Therapeutics, Inc. Address of Principal Business Office or, if none, Residence		
	(6)	TorreyPines Therapeutics, Inc.		
		11085 North Torrey Pines Road, Suite 300		
		La Jalla CA 02027		
	(c)	La Jolla, CA 92037 Citizenship		
	(C)	Delaware		
	(d)	Title of Class of Securities		
		Common Shares, par value \$0	0.001	
	(e)	CUSIP Number		
		691892402		
Item 3. If this statement is filed pursuant to §§240.13d-1(b)			or 240.13d-2(b) or (c), check whether the person filing is a:	
		-	Broker or dealer registered under section 15 of the Act (15 U.S.C.	
	(a)	0	780).	
	(b)	0	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).	
	(c)	0	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).	
	(d)	o	Investment company registered under section 8 of the Investment	
			Company Act of 1940 (15 U.S.C 80a-8).	
	(e)	О	An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);	
	(f)	0	An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);	
	(g)	o	A parent holding company or control person in accordance with §	
			240.13d-1(b)(1)(ii)(G);	
	(h)	0	A savings associations as defined in Section 3(b) of the Federal	
	(i)		Deposit Insurance Act (12 U.S.C. 1813);	
	(i)	0	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of	
			1940 (15 U.S.C. 80a-3);	
			· · · · · · · · · · · · · · · · · · ·	
	(j)	o	Group, in accordance with §240.13d-1(b)(1)(ii)(J).	

Item 4. Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned:

13,982,567

(b) Percent of class:

31.4%

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote

13,982,567

(ii) Shared power to vote or to direct the vote

0

(iii) Sole power to dispose or to direct the disposition of

13,982,567

(iv) Shared power to dispose or to direct the disposition of

0

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following O.

N/A

Item 6. Ownership of More than Five Percent on Behalf of Another Person

N/A

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding

Company or Control Person

N/A

Item 8. Identification and Classification of Members of the Group

N/A

Item 9. Notice of Dissolution of Group

N/A

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such

purpose or effect.

4

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 14, 2007 (Date)

TorreyPines Therapeutics, Inc.

By: /s/ Craig Johnson

Name: Craig Johnson

Title: Vice President, Finance and

Chief Financial Officer

5

Signature 6